Journal: International Journal of Molecular Sciences

Article Title: Echinacoside as a Novel Ferroptosis Inducer in Hepatocellular Carcinoma: Mechanistic Insights from TP53/SLC7A11/GPX4 Pathway Modulation

doi: 10.3390/ijms27010411

Figure Lengend Snippet: The results of HCC cell growth inhibited by ECH. ( A ) HepG2 cells were treated with different concentrations of ECH for 24 h. ( B ) Huh7 cells were treated with different concentrations of ECH for 24 h. ( C ) LO2 cells were treated with different concentrations of ECH for 24 h. Abbreviations: ECH: echinacoside. HCC: hepatocellular carcinoma. IC 50 : half-maximal inhibitory concentration.

Article Snippet: The human normal hepatocytes cell line LO2, human hepatoblastoma cell line HepG2, and human hepatocellular carcinoma (HCC) cell line HuH7 were obtained from Procell (Wuhan, China).

Techniques: Concentration Assay

Journal: Molecules

Article Title: Isolation, Characterization, Moisturization and Anti-HepG2 Cell Activities of a Novel Polysaccharide from Cyanobacterium aponinum

doi: 10.3390/molecules29194556

Figure Lengend Snippet: Cytotoxicity activity of CAP on LO2 and HepG2 cells in vitro. The cell viability of LO2 treated with different concentrations of CAP (0.0, 0.1, 0.5, 1.0, 5.0, 10.0, 20.0, 50.0, 100.0 µg mL −1 ) for 48 h ( a ) and the growth inhibition rate of CAP with same concentrations on HepG2 cell after 48 h treatment. Gemcitabine was used as a positive control ( b ).

Article Snippet: The cytotoxicity of CAP on human fetal hepatocyte cell line LO2 (purchased from iCell Bioscience Inc., Shanghai, China) was evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.

Techniques: Activity Assay, In Vitro, Inhibition, Positive Control

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: NAFLD models established to investigate changes in AC012668 expression. (a) Heat map of differentially expressed lncRNAs in NAFLD. (b) Cell viability and (c and d) apoptosis of LO2 cells treated with FFA. (e and f) Oil-Red O staining image and TG level in the liver tissues of HFD mice. (g) AC012668 expression levels in the liver tissues of HFD mice. (h) Expression of AC012668 in FFA-treated cells. *P < 0.05 vs. control; **P < 0.01 vs. control

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Expressing, Staining

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: AC012668 suppresses TG/lipid accumulation and lipogenesis in LO2 cells. (a) AC012668 expression level in FFA-treated LO2 cells transfected with the AC012668 overexpression plasmid. (b) mRNA and (c and d) protein expression levels of SCD1, SREBP1 , and FAS in FFA-treated LO2 cells. (e) TG level and (f) Oil-Red O staining in FFA-treated LO2 cells. *P < 0.05 vs. pcDNA3.1 or AC012668.

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Expressing, Transfection, Over Expression, Plasmid Preparation, Staining

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: miR-380-5p directly targets AC012668 . (a) Wild and mutant types of AC012668 reporters labeled with luciferase. (b) Expression levels of miR-380-5p in AC012668 -enhanced/-inhibited LO2 cells. (c) Relative luciferase activities in wild-type and mutant AC012668 groups compared with the mimic negative control group. (d) Relative enrichment of AC012668 in the biotinylated miR-380-5p group. (e) AC012668 expression levels in the liver tissues of HFD mice. (f) Expression level of miR-380-5p in LO2 cells treated with 1 mM FFA. *P < 0.05 vs. biotin-NC; **P < 0.01 vs. si-NC, vector, mimic NC, or control

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Mutagenesis, Labeling, Luciferase, Expressing, Negative Control, Plasmid Preparation

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: miR-380-5p promotes TG/lipid accumulation and lipogenesis in LO2 cells transfected with AC012668 . (a) AC012668 expression detected using reverse transcription-quantitative polymerase chain reaction. (b) mRNA and (c and d) protein levels of SCD1, SREBP1 , and FAS . (e) TG level and (f) lipid deposition. *P < 0.05 vs. AC012668 + mimic NC; **P < 0.01 vs. vector

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Transfection, Expressing, Real-time Polymerase Chain Reaction, Plasmid Preparation

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: LRP2 is a target of miR-380-5p . (a) Wild and mutant types of LRP2 reporters labeled with luciferase. (b) mRNA expression of LRP2 in FFA-treated LO2 cells transfected with the miR-380-5p mimic or inhibitor. (c) Relative luciferase activities in wild-type and mutant LRP2 groups compared with the mimic negative control group. (d) Relative enrichment of LRP2 in the biotinylated miR-380-5p group. (e) AC012668 expression levels in the liver tissues of HFD mice. (f) Expression level of LRP2 in FFA-treated LO2 cells. *P < 0.05 vs. biotin-NC; **P < 0.01 vs. inhibitor NC, mimic NC, or control

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Mutagenesis, Labeling, Luciferase, Expressing, Transfection, Negative Control

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: Effects of LRP2 knockdown on TG/lipid accumulation and lipogenesis in miR-380-5p -inhibited LO2 cells. (a) miR-380-5p expression level in LO2 cells cotransfected with the miR-380-5p inhibitor and si-LRP2 . (b) mRNA and (c and d) protein levels of SCD1, SREBP1 , and FAS in the miR-380-5p inhibitor- and si-LRP2 -cotransfected cells. (e) TG level and (f) lipid deposition in the miR-380-5p inhibitor- and si-LRP2 -cotransfected cells. *P < 0.05 vs. control or miR-380-5p mimic + si-NC

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Expressing